top of page
About
Services
Contact
Blog
More
Use tab to navigate through the menu items.
Recent Posts
CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs
On February 18, 2021, the Congressional Budget Office (CBO) published a report entitled, A Comparison of Brand-Name Drug Prices Among...
The Impact of Single Indication Orphan Drugs on the Future of Rare Diseases
What is the impact of rare diseases on individuals and health care systems?
Congressionally funded report details diagnostic challenges and costs of rare diseases in the US
Diagnostics: Moving to the forefront of Global Healthcare
Economic Burden of Rare Diseases Nearly $1 Trillion
CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs
Orphan drugs account for more than half of all FDA drug approvals in 2020
Rare Disease Stakeholders: Do mRNA COV19 Vaccines Affect Eligibility to Receive Future Gene Therapy?
How do we identify and measure value for patients with rare diseases?
National Burden of Rare Disease Survey
bottom of page
